These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37771992)

  • 1. Retracted: Clinical Effect of Qili Qiangxin Capsule Combined with Sacubitril-Valsartan in Patients with Chronic Heart Failure.
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9756013. PubMed ID: 37771992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effect of Qili Qiangxin Capsule Combined with Sacubitril-Valsartan in Patients with Chronic Heart Failure.
    Yao J; Liu D
    J Healthc Eng; 2022; 2022():8598806. PubMed ID: 35368935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis.
    Xiang Q; Wang M; Ding Y; Fan M; Tong H; Chen J; Yu P; Shen L; Chen X
    Front Pharmacol; 2022; 13():832782. PubMed ID: 35444529
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical effects of a standardized Chinese herbal remedy, Qili Qiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis.
    Sun J; Zhang K; Xiong WJ; Yang GY; Zhang YJ; Wang CC; Lai L; Han M; Ren J; Lewith G; Liu JP
    BMC Complement Altern Med; 2016 Jul; 16():201. PubMed ID: 27402016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure.
    Li X; Zhang J; Huang J; Ma A; Yang J; Li W; Wu Z; Yao C; Zhang Y; Yao W; Zhang B; Gao R;
    J Am Coll Cardiol; 2013 Sep; 62(12):1065-1072. PubMed ID: 23747768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy of Qili Qiangxin Capsule Combined with Western Medicine in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis.
    Xu X; Yang Y; Zhou G; Du Z; Zhang X; Mao W; Cai H
    Evid Based Complement Alternat Med; 2021; 2021():9761159. PubMed ID: 34408783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of Qili Qiangxin Capsule combined with exercise rehabilitation in the treatment of chronic heart failure.
    Zhu M; Chen L; Xu Z; Xi X; Shi X; Zhang Y
    Explore (NY); 2023; 19(3):445-449. PubMed ID: 36307314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative analysis of clinical effects according to syndrome differentiation of Qili Qiangxin Capsules on ischemic heart failure: Meta-analysis].
    Sun YL; Ruan XF; Li YP; Wang XL
    Zhongguo Zhong Yao Za Zhi; 2019 Nov; 44(22):4975-4984. PubMed ID: 31872608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qili Qiangxin (QLQX) capsule as a multi-functional traditional Chinese medicine in treating chronic heart failure (CHF): A review of ingredients, molecular, cellular, and pharmacological mechanisms.
    Wang T; Hou B; Qin H; Liang J; Shi M; Song Y; Ma K; Chen M; Li H; Ding G; Yao B; Wang Z; Wei C; Jia Z
    Heliyon; 2023 Nov; 9(11):e21950. PubMed ID: 38034785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional Chinese medicine Qili qiangxin inhibits cardiomyocyte apoptosis in rats following myocardial infarction.
    Xiao J; Deng SB; She Q; Li J; Kao GY; Wang JS; Ma YU
    Exp Ther Med; 2015 Nov; 10(5):1817-1823. PubMed ID: 26640555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Qili Qiangxin Capsule on AQP2, V2R, and AT1R in Rats with Chronic Heart Failure.
    Cui X; Zhang J; Li Y; Sun Y; Cao J; Zhao M; Zhao Y; Zhao X; He Y; Han A
    Evid Based Complement Alternat Med; 2015; 2015():639450. PubMed ID: 26074997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of enhanced external counter pulsation plus sacubitril/valsartan in the treatment of patients with chronic heart failure and the effect on ankle-arm index and cardiac function.
    Huang XL; Wang XJ; Chen BT; Chen YN
    Eur Rev Med Pharmacol Sci; 2023 Apr; 27(8):3300-3312. PubMed ID: 37140280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of a Qiliqiangxin Capsule Combined with Sacubitril/Valsartan in the Treatment of Chronic Heart Failure: A Systematic Review and Meta-Analysis.
    Chen W; Chang H; Wang X; Wang Y; Liu Y; Wang D
    Evid Based Complement Alternat Med; 2023; 2023():2701314. PubMed ID: 36777628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of Sacubitril/Valsartan in the treatment of chronic heart failure: a meta-analysis.
    Zheng C; Dai H; Huang J; Lin M; Zheng Q; Tang P; Xiao J; Zhang Y
    Am J Transl Res; 2021; 13(11):12114-12128. PubMed ID: 34956440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Naser N; Kulić M; Jatić Z
    Med Arch; 2022 Apr; 76(2):101-107. PubMed ID: 35774049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
    Gandotra C; Clark J; Liu Q; Senatore FF; Rose M; Zhang J; Stockbridge NL
    Ther Innov Regul Sci; 2022 Jan; 56(1):4-7. PubMed ID: 34699047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Mann DL; Givertz MM; Vader JM; Starling RC; Shah P; McNulty SE; Anstrom KJ; Margulies KB; Kiernan MS; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; DeVore AD; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JAMA Cardiol; 2022 Jan; 7(1):17-25. PubMed ID: 34730769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Network Meta-analysis of six Chinese patent medicines for replenishing Qi and activating blood in treatment of chronic heart failure].
    Park YS; Wang W; Li YD; Liu K
    Zhongguo Zhong Yao Za Zhi; 2022 Aug; 47(15):4221-4237. PubMed ID: 36046913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.